Phase 4Status unknown
Azelnidipine in patients with Essential Hypertension
Evaluation of Efficacy and Safety of Azelnidipine in Patients with Essential Hypertension based on 24-h Ambulatory Blood Pressure Monitoring: A Randomized, Assessor-blind Comparison with Cilnidipine - AZCI/PIV-21
- Sponsor
- Ipca Laboratories Ltd
- Enrolment
- 108 planned
- Conditions
- Health Condition 1: I10- Essential (primary) hypertension
- Interventions
- Azelnidipine
- Registry
- CTRI-2026-08-116748
Full record on the Clinical Trials Registry – IndiaSource: WHO ICTRP, processed 14 September 2026
Primary outcomes
- To evaluate and compare mean change in 24 h ambulatory SBP between azelnidipine group and cilnidipine group <br/ > Timepoint: at week 12 from baseline <br/ >
History
Started
Last registry update
Registered